missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Biliverdin Reductase Polyclonal Antibody, Invitrogen™
Description
PA1-019 detects biliverdin-IX alpha reductase (BLVRA) from human cells. PA1-019 has been successfully used in Western blot procedures. By Western blot, this antibody detects an ∽40 kDa protein representing BLVRA from HeLa cell extract. The PA1-019 immunogen is purified human biliverdin reductase expressed in E. coli.
Biliverdin reductase (BLVR) is a ubiquitously expressed, small cytoplasmic oxidoreductase that catalyzes the reduction of biliverdin to bilirubin. The first step of this process is catalyzed by heme oxygenase, an enzyme that converts heme to iron, carbon monoxide, and biliverdin. BLVR is unique among all enzymes to date in being dual pH/dual cofactor-dependent, as it requires NADH (pH 6.7) or NADPH (pH 8.7) as an electron donor. There are two isoforms of BLVR, biliverdin-IX alpha-reductase (BLVRA), the major component of human adult liver, and biliverdin–IX beta-reductase (BLVRB), found predomitly in fetal liver. The product of BLVR, bilirubin, is an important biological antioxidant, however it is also a neurotoxin and the cause of kernicterus. In addition to being an antioxidant, it inhibits kinase activity and the activity of enzymes such as protein kinase C and NADPH oxidase.
Specifications
Specifications
| Antigen | Biliverdin Reductase |
| Applications | Western Blot |
| Classification | Polyclonal |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 1mg/mL BSA and 0.05% sodium azide |
| Gene | BLVRA |
| Gene Accession No. | P53004 |
| Gene Alias | BLVRA, Biliverdin reductase A, EC 1.3.1.24, BVR A |
| Gene Symbols | BLVRA |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?